Literature DB >> 10358032

RIP3, a novel apoptosis-inducing kinase.

X Sun1, J Lee, T Navas, D T Baldwin, T A Stewart, V M Dixit.   

Abstract

RIP3 is a novel gene product containing a N-terminal kinase domain that shares extensive homology with the corresponding domain in RIP (receptor-interacting protein) and RIP2. Unlike RIP, which has a C-terminal death domain, and RIP2, which has a C-terminal caspase activation and recruitment domain, RIP3 has a unique C terminus. RIP3 binds RIP through its unique C-terminal segment and by virtue of this interaction is recruited to the tumor necrosis factor (TNF) receptor-1 signaling complex. Previous studies have shown that RIP mediates TNF-induced activation of the anti-apoptotic NF-kappaB pathway. RIP3, however, attenuates both RIP and TNF receptor-1-induced NF-kappaB activation. Overexpression studies revealed RIP3 to be a potent inducer of apoptosis, capable of selectively binding to large prodomain initiator caspases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358032     DOI: 10.1074/jbc.274.24.16871

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  91 in total

1.  The necroptosis adaptor RIPK3 promotes injury-induced cytokine expression and tissue repair.

Authors:  Kenta Moriwaki; Sakthi Balaji; Thomas McQuade; Nidhi Malhotra; Joonsoo Kang; Francis Ka-Ming Chan
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

Review 2.  Photoreceptor cell death and rescue in retinal detachment and degenerations.

Authors:  Yusuke Murakami; Shoji Notomi; Toshio Hisatomi; Toru Nakazawa; Tatsuro Ishibashi; Joan W Miller; Demetrios G Vavvas
Journal:  Prog Retin Eye Res       Date:  2013-08-28       Impact factor: 21.198

3.  Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.

Authors:  James R Cerhan; Stephen M Ansell; Zachary S Fredericksen; Neil E Kay; Mark Liebow; Timothy G Call; Ahmet Dogan; Julie M Cunningham; Alice H Wang; Wen Liu-Mares; William R Macon; Diane Jelinek; Thomas E Witzig; Thomas M Habermann; Susan L Slager
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

Review 4.  Structural basis of signal transduction in the TNF receptor superfamily.

Authors:  Jixi Li; Qian Yin; Hao Wu
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

5.  Cell biology. RIPK3 takes another deadly turn.

Authors:  Jianke Zhang; Francis Ka-Ming Chan
Journal:  Science       Date:  2014-03-21       Impact factor: 47.728

6.  RIP3 induces apoptosis independent of pronecrotic kinase activity.

Authors:  Pratyusha Mandal; Scott B Berger; Sirika Pillay; Kenta Moriwaki; Chunzi Huang; Hongyan Guo; John D Lich; Joshua Finger; Viera Kasparcova; Bart Votta; Michael Ouellette; Bryan W King; David Wisnoski; Ami S Lakdawala; Michael P DeMartino; Linda N Casillas; Pamela A Haile; Clark A Sehon; Robert W Marquis; Jason Upton; Lisa P Daley-Bauer; Linda Roback; Nancy Ramia; Cole M Dovey; Jan E Carette; Francis Ka-Ming Chan; John Bertin; Peter J Gough; Edward S Mocarski; William J Kaiser
Journal:  Mol Cell       Date:  2014-11-20       Impact factor: 17.970

7.  The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis.

Authors:  Jixi Li; Thomas McQuade; Ansgar B Siemer; Johanna Napetschnig; Kenta Moriwaki; Yu-Shan Hsiao; Ermelinda Damko; David Moquin; Thomas Walz; Ann McDermott; Francis Ka-Ming Chan; Hao Wu
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

Review 8.  The Inflammatory Signal Adaptor RIPK3: Functions Beyond Necroptosis.

Authors:  K Moriwaki; F K-M Chan
Journal:  Int Rev Cell Mol Biol       Date:  2016-09-22       Impact factor: 6.813

9.  Death-associated protein kinase-related protein 1, a novel serine/threonine kinase involved in apoptosis.

Authors:  B Inbal; G Shani; O Cohen; J L Kissil; A Kimchi
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

Review 10.  Programmed necrosis in the cross talk of cell death and inflammation.

Authors:  Francis Ka-Ming Chan; Nivea Farias Luz; Kenta Moriwaki
Journal:  Annu Rev Immunol       Date:  2014-12-10       Impact factor: 28.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.